Neuphoria Therapeutics (NASDAQ:NEUP) Announces Quarterly Earnings Results

Neuphoria Therapeutics (NASDAQ:NEUP) announced its quarterly earnings results on Tuesday. The company reported ($0.77) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.21), Zacks reports.

Neuphoria Therapeutics Price Performance

NASDAQ NEUP remained flat at $4.05 during trading hours on Tuesday. The company had a trading volume of 13,108 shares, compared to its average volume of 37,245. The stock has a 50-day simple moving average of $4.00 and a 200 day simple moving average of $7.27. Neuphoria Therapeutics has a 1 year low of $3.64 and a 1 year high of $21.40. The firm has a market capitalization of $21.78 million, a price-to-earnings ratio of -0.83 and a beta of 0.52.

Institutional Investors Weigh In On Neuphoria Therapeutics

A number of institutional investors have recently bought and sold shares of the stock. Commonwealth Equity Services LLC acquired a new position in Neuphoria Therapeutics during the fourth quarter worth approximately $43,000. Persistent Asset Partners Ltd grew its stake in shares of Neuphoria Therapeutics by 173.1% during the 4th quarter. Persistent Asset Partners Ltd now owns 13,403 shares of the company’s stock valued at $52,000 after buying an additional 8,495 shares during the period. Geode Capital Management LLC grew its stake in shares of Neuphoria Therapeutics by 33.3% during the 4th quarter. Geode Capital Management LLC now owns 17,303 shares of the company’s stock valued at $67,000 after buying an additional 4,325 shares during the period. Diadema Partners LP increased its holdings in shares of Neuphoria Therapeutics by 133.1% during the 4th quarter. Diadema Partners LP now owns 50,000 shares of the company’s stock worth $194,000 after buying an additional 28,548 shares during the last quarter. Finally, Millennium Management LLC purchased a new position in shares of Neuphoria Therapeutics in the 3rd quarter worth $216,000. 15.90% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on NEUP shares. Wall Street Zen downgraded shares of Neuphoria Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, November 23rd. Zacks Research upgraded shares of Neuphoria Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Tuesday, February 3rd. HC Wainwright cut their price objective on Neuphoria Therapeutics from $21.00 to $7.00 and set a “buy” rating for the company in a research report on Friday, December 5th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Neuphoria Therapeutics in a research note on Thursday, January 22nd. Two equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $21.00.

Neuphoria Therapeutics Company Profile

Neuphoria Therapeutics, Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.